The Monash Health Pathology team’s implementation of pan-cancer genomic testing has put it at the forefront of cancer care and presented staff with a valuable learning opportunity.
We are delighted to share that the service has received accreditation from the National Association of Testing Authorities (NATA). Accreditation recognises the quality and accuracy of the team’s genetic testing processes.
“We started molecular work at Monash Health in 2023. We have grown so fast. It has been amazing,” said Program Director of Pathology at Monash Health, Dr Beena Kumar.
The Roche AVENIO pan-cancer genomic test for patients diagnosed with a tumour, screens for nearly 400 cancer-related genes.
The comprehensive results attained enable oncologists to develop more personalised treatment plans.
This tailored approach can lead to more effective treatments, fewer side effects, and better patient outcomes.
The results help identify patients eligible for enrolment in clinical trials.
“Clinical trials are based on the presence or absence of mutations. If a patient has a mutation, then they can go into a particular clinical trial. We include in our reports the trials they are eligible to get into,” Dr Kumar said.
For our scientific and clinical teams, the introduction of advanced technology has enhanced diagnostic precision and supported more efficient workflows.
“The integration of these complex technologies has also provided valuable educational opportunities, enabling our teams to continuously expand their knowledge and expertise in cutting-edge genomic medicine,” said Lead Technical Scientist-Diagnostic Genomics, Dr Ravikiran Vedururu.
“This initiative reflects our commitment to improving community wellbeing and care through thoughtful integration and ongoing learning.”
To enquire about the test, please contact genomics@monashhealth.org.
